Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2023

May 04, 2023

BUY
$37.27 - $50.24 $223 - $301
6 Added 6.38%
100 $3,000
Q4 2022

Feb 03, 2023

BUY
$33.44 - $54.8 $1,371 - $2,246
41 Added 77.36%
94 $5,000
Q3 2022

Nov 02, 2022

BUY
$10.15 - $34.05 $537 - $1,804
53 New
53 $2,000

Others Institutions Holding AKRO

About Akero Therapeutics, Inc.


  • Ticker AKRO
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 46,417,600
  • Market Cap $1.42B
  • Description
  • Akero Therapeutics, Inc., a cardio-metabolic nonalcoholic steatohepatitis (NASH) company, engages in the development of medicines designed to restore metabolic balance and improve overall health. The company's lead product candidate is efruxifermin (EFX), an analog of fibroblast growth factor 21, which protects against cellular stress and regula...
More about AKRO
Track This Portfolio

Track Ellevest, Inc. Portfolio

Follow Ellevest, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Ellevest, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Ellevest, Inc. with notifications on news.